Clinical trial
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That…
NCT00085020 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00085020 |
|---|---|
| Title | GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu |
| Official title | A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Trastuzumab [Herceptin†] |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, lapatinib ditosylate |
| Enrollment | 13 |
| Start date | Mar 1, 2004 |
| Primary completion | Dec 1, 2004 |
| Completion | Feb 1, 2005 |
| First posted | Jun 11, 2004 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: